Shanghai Hile Bio-Technology Co., Ltd.
SSE:603718.SS
7.26 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 271.04 | 240.723 | 299.992 | 347.289 | 259.129 | 277.993 | 254.565 | 303.65 | 343.339 | 316.578 | 285.272 | 318.793 | 310.843 | 260.127 |
| Cost of Revenue
| 107.862 | 117.005 | 123.088 | 153.615 | 137.761 | 148.708 | 112.417 | 69.223 | 84.027 | 73.531 | 61.801 | 71.075 | 69.07 | 61.515 |
| Gross Profit
| 163.178 | 123.718 | 176.903 | 193.674 | 121.367 | 129.285 | 142.148 | 234.427 | 259.311 | 243.047 | 223.471 | 247.718 | 241.773 | 198.613 |
| Gross Profit Ratio
| 0.602 | 0.514 | 0.59 | 0.558 | 0.468 | 0.465 | 0.558 | 0.772 | 0.755 | 0.768 | 0.783 | 0.777 | 0.778 | 0.764 |
| Reseach & Development Expenses
| 21.44 | 24.972 | 29.944 | 28.64 | 29.525 | 29.643 | 27.284 | 20.159 | 20.714 | 19.68 | 17.86 | 14.929 | 14.327 | 0 |
| General & Administrative Expenses
| 36.091 | 35.261 | 20.117 | 10.861 | 22.481 | 19.132 | 20.589 | 10.183 | 11.073 | 8.819 | 47.694 | 39.427 | 37.35 | 32.658 |
| Selling & Marketing Expenses
| 33.376 | 40.832 | 57.741 | 79.468 | 51.789 | 59.299 | 70.458 | 97.172 | 116.15 | 91.014 | 76.329 | 79.03 | 78.916 | 52.094 |
| SG&A
| 69.467 | 49.553 | 77.858 | 90.33 | 74.269 | 78.43 | 91.047 | 107.355 | 127.223 | 99.833 | 124.023 | 118.457 | 116.266 | 84.752 |
| Other Expenses
| -105.27 | -24.082 | -5.842 | 36.954 | 28.222 | 23.765 | -23.406 | 2.287 | 4.172 | -1.243 | 12.312 | 7.391 | 5.223 | 9.561 |
| Operating Expenses
| -11.348 | 65.251 | 101.96 | 155.924 | 132.017 | 131.839 | 137.819 | 140.569 | 196.155 | 145.477 | 124.964 | 119.82 | 117.576 | 85.953 |
| Operating Income
| 174.526 | 55.171 | 152.568 | 57.242 | 12.466 | 29.588 | 22.178 | 104.836 | 73.11 | 109.613 | 104.731 | 132.189 | 126.835 | 116.727 |
| Operating Income Ratio
| 0.644 | 0.229 | 0.509 | 0.165 | 0.048 | 0.106 | 0.087 | 0.345 | 0.213 | 0.346 | 0.367 | 0.415 | 0.408 | 0.449 |
| Total Other Income Expenses Net
| 33.591 | 0.852 | -21.351 | -0.102 | -35.808 | -22.761 | -23.406 | 2.287 | 4.172 | -1.269 | 12.277 | 7.15 | 7.667 | 9.561 |
| Income Before Tax
| 208.117 | 56.022 | 131.217 | 57.139 | -23.342 | 6.827 | -1.228 | 107.123 | 76.894 | 108.344 | 117.007 | 139.339 | 131.864 | 126.288 |
| Income Before Tax Ratio
| 0.768 | 0.233 | 0.437 | 0.165 | -0.09 | 0.025 | -0.005 | 0.353 | 0.224 | 0.342 | 0.41 | 0.437 | 0.424 | 0.485 |
| Income Tax Expense
| 26.482 | 6.009 | 20.526 | 11.473 | 8.811 | 33.237 | 12.48 | 11.828 | 6.849 | 17.01 | 17.172 | 20.917 | 19.318 | 19.014 |
| Net Income
| 171.18 | 62.87 | 121.608 | 53.857 | -32.152 | -26.41 | 21.298 | 113.74 | 85.536 | 95.403 | 101.221 | 118.79 | 112.546 | 107.273 |
| Net Income Ratio
| 0.632 | 0.261 | 0.405 | 0.155 | -0.124 | -0.095 | 0.084 | 0.375 | 0.249 | 0.301 | 0.355 | 0.373 | 0.362 | 0.412 |
| EPS
| 0.27 | 0.1 | 0.19 | 0.084 | -0.05 | -0.041 | 0.03 | 0.18 | 0.13 | 0.17 | 0.21 | 0.23 | 0.22 | 0.2 |
| EPS Diluted
| 0.26 | 0.1 | 0.19 | 0.084 | -0.05 | -0.041 | 0.03 | 0.18 | 0.13 | 0.17 | 0.21 | 0.23 | 0.22 | 0.2 |
| EBITDA
| 251.033 | 101.12 | 183.281 | 120.473 | 59.725 | 93.149 | 70.874 | 116.712 | 134.308 | 138.319 | 126.709 | 164.631 | 154.207 | 123.224 |
| EBITDA Ratio
| 0.926 | 0.42 | 0.611 | 0.347 | 0.23 | 0.335 | 0.278 | 0.384 | 0.391 | 0.437 | 0.444 | 0.516 | 0.496 | 0.474 |